What Does WHI E-alone Tell Us About the Cost-Effectiveness of Estrogen Therapy?

At a glance

| Parameter | Detail | |---|---| | Trial | WHI Estrogen-Alone (E-alone) | | N | 10,739 hysterectomized postmenopausal women | | Intervention | Conjugated equine estrogen (CEE) 0.625 mg/day | | Comparator | Placebo | | Duration | Median 7.2 years (stopped early by NIH) | | Primary endpoint | Coronary heart disease (nonfatal MI + CHD death) | | Key result | No overall CHD benefit; reduced breast cancer incidence (HR 0.77); age-stratified analyses showed CHD reduction in women aged 50-59 (Anderson et al., 2004) |

Why an Economic Analysis of WHI E-alone Matters

The WHI combined-therapy arm (estrogen plus progestin) generated enormous concern about HRT costs to payers because the treatment appeared to cause net harm. The estrogen-alone arm told a different story. CEE monotherapy in hysterectomized women showed a non-significant trend toward reduced coronary events, a statistically significant reduction in breast cancer, and a modest increase in stroke risk. That mixed clinical profile creates exactly the kind of tradeoff where formal cost-effectiveness analysis (CEA) becomes essential for coverage decisions and clinical shared decision-making.

Generic CEE (Premarin and equivalents) is also inexpensive compared to newer estradiol formulations, patches, and compounded preparations, which makes the cost side of the equation unusually favorable.

The Primary CEA Models Built on WHI E-alone Data

Manson / Aragaki 50-59 Subgroup Reanalysis

The most influential post-hoc economic framing came not from a standalone CEA publication but from the age-stratified reanalysis of WHI endpoints. Manson et al. (2007) demonstrated that women aged 50 to 59 at enrollment had a hazard ratio of 0.63 for the composite of MI, coronary revascularization, and CHD death. When combined with the breast cancer reduction (HR 0.77 across the full cohort in the primary 2004 publication), the net clinical benefit in this subgroup was strongly positive.

Health economists subsequently used these subgroup hazard ratios as inputs. Under standard Markov modeling with a 10-year horizon:

| Age at initiation | Incremental cost (2024 USD, estimated) | Incremental QALYs | ICER | |---|---|---|---| | 50-54 | -$1,200 to +$3,400 | +0.04 to +0.09 | Dominant to ~$38,000/QALY | | 55-59 | +$800 to +$5,100 | +0.02 to +0.06 | ~$14,000 to ~$85,000/QALY | | 60-69 | +$4,500 to +$9,800 | -0.01 to +0.02 | Dominated or >$200,000/QALY | | 70-79 | +$7,000 to +$14,000 | -0.03 to -0.01 | Dominated (net harm) |

Table synthesized from published model ranges across multiple CEA publications; costs inflation-adjusted.

The pattern is clear. For younger postmenopausal women, CEE monotherapy is either cost-saving (the CHD and breast cancer reductions offset drug and monitoring costs) or well below standard willingness-to-pay thresholds. For women over 65, the stroke signal from the original WHI E-alone trial dominates the model, pushing incremental cost-effectiveness ratios above any reasonable threshold.

Salpeter Meta-Analytic CEA

Salpeter et al. pooled WHI E-alone with other estrogen-only trials and found that younger-start HRT reduced total mortality (OR 0.68 to 95% CI 0.48 to 0.96). When this mortality benefit was fed into a lifetime Markov model, CEE for women starting at age 50 was dominant in the base case, meaning it saved money and extended quality-adjusted life. Sensitivity analysis showed the result remained cost-effective up to a drug cost roughly four times the actual generic price.

Lekander / Swedish Adaptation

European adaptations produced similar conclusions. Lekander et al. adapted the WHI E-alone subgroup data to a Swedish cost structure and found CEE cost-effective at conventional thresholds (SEK 500,000 per QALY, roughly $50,000) for women aged 50 to 60 with vasomotor symptoms. The model was conservative: it excluded quality-of-life gains from symptom relief and counted only hard endpoint shifts.

Drug Cost Reality: List Price vs. Net Price

Understanding the economic argument requires knowing what CEE actually costs at the pharmacy counter.

Brand Premarin (0.625 mg): Average wholesale price hovers around $250 to $320 for a 30-day supply, depending on the distributor. Most insured patients pay a tier-2 copay of $20 to $45 per month. The FDA-approved labeling for Premarin covers the full range of menopausal indications plus osteoporosis prevention in hysterectomized women, which is directly relevant to the WHI E-alone population.

Generic conjugated estrogens: Since the introduction of generic alternatives (synthetic conjugated estrogens and generic CEE formulations), retail cash prices have dropped to $15 to $60 per month at major pharmacies. GoodRx-type discount cards push the effective price to $8 to $25 in many markets.

Transdermal estradiol patches (comparator): While not the intervention studied in WHI E-alone, patches are a common alternative. Generic estradiol patches cost $15 to $40 per month; brand patches (Climara, Vivelle-Dot) range from $150 to $250 per month without insurance.

The practical consequence: in most CEA models, the drug acquisition cost is a minor input. Monitoring costs (periodic mammography, pelvic exams, lipid panels) and downstream event costs (MI hospitalizations, stroke care, breast cancer treatment) dominate the model.

Payer Coverage Patterns

Following the initial WHI combined-therapy scare in 2002, many insurers imposed prior authorization requirements on all HRT products. The estrogen-alone results published in 2004 and subsequent favorable age-stratified data gradually relaxed these barriers, but inconsistently.

Current coverage patterns across major payer types:

• Commercial plans: Most cover generic CEE at tier 1 or 2 without prior authorization for women under 60. Brand Premarin typically requires step therapy (try generic first).
• Medicare Part D: CEE is covered under most Part D formularies. The low cost means it rarely triggers coverage-gap ("donut hole") concerns even for patients on multiple medications.
• Medicaid: Coverage varies by state. Most state Medicaid programs cover generic CEE. A handful require prior authorization documenting menopausal symptoms.
• VA system: The VA formulary includes CEE. Copays are $5 to $11 for a 30-day supply for most veterans.

One underappreciated friction point: compounded bioidentical hormone preparations, which are not FDA-approved and were not studied in WHI, are typically not covered by any payer. Women who choose compounded products over generic CEE bear the full cost ($40 to $200 per month), which sharply worsens their personal cost-effectiveness ratio compared to what the WHI E-alone data supports.

The Relative-Value Calculation for Individual Patients

Population-level cost-effectiveness is useful for formulary committees and guideline panels. Individual patients face a different question: Is this medication worth it for me?

For a 52-year-old hysterectomized woman with moderate vasomotor symptoms, the math works out favorably on nearly every axis:

1. Symptom relief: WHI E-alone documented significant improvement in hot flash frequency and severity. At a generic cost of $15 per month, this is cheaper than most over-the-counter supplement regimens marketed for menopause.
2. Breast cancer signal: The HR of 0.77 for invasive breast cancer in the full WHI E-alone cohort translates to approximately 6 fewer cases per 10,000 women-years. For a woman with average breast cancer risk, this is a meaningful secondary benefit.
3. Bone density: CEE produced significant improvements in hip and spine bone mineral density in WHI E-alone. For a woman with osteopenia, this may defer or eliminate the need for bisphosphonates ($200 to $1,800 per year) or denosumab ($1,600 to $2,400 per year).
4. Cardiovascular trade-off: The modest stroke risk increase (HR 1.39 overall, but attenuated in the 50-59 subgroup) must be weighed against the CHD reduction in younger women. For a woman with low baseline stroke risk (no hypertension, no atrial fibrillation, non-smoker), the net cardiovascular balance may favor treatment.

The value proposition deteriorates for women initiating CEE after age 65, those with elevated stroke risk factors, or those without bothersome vasomotor symptoms (where the quality-of-life numerator shrinks).

Limitations of Existing Economic Models

Every published CEA built on WHI E-alone data shares structural limitations that readers should understand:

Subgroup-derived inputs. The favorable cost-effectiveness in younger women depends on age-stratified hazard ratios from a trial that was not powered or randomized by age group. The primary publication reported overall hazard ratios; age-specific results came from post-hoc analyses. This is a legitimate scientific concern, though the consistency of the age-timing signal across WHI arms, observational cohorts, and the ELITE trial provides indirect support.

Symptom QALY assumptions. Models that include quality-of-life gains from vasomotor symptom relief produce substantially better ICERs than those limited to hard endpoints. The magnitude of the QALY gain from symptom relief is uncertain and varies across utility-measurement instruments.

No long-term follow-up costs. Most models used a 10 to 20 year horizon. The WHI post-intervention follow-up (median 13 years total) showed that the breast cancer benefit persisted after stopping CEE, which would improve lifetime cost-effectiveness. But no published model has fully incorporated the extended follow-up data from LaCroix et al. (2011).

Single-dose assumption. WHI E-alone tested 0.625 mg CEE only. Lower doses (0.3 mg, 0.45 mg), which are commonly prescribed today, might have different risk-benefit profiles and different cost-effectiveness. No RCT of comparable size has evaluated lower-dose CEE against hard endpoints.

What Guideline Bodies Say About Economic Value

The North American Menopause Society (NAMS) 2022 position statement endorses HRT as cost-effective for symptomatic women within 10 years of menopause or under age 60, citing WHI data including the E-alone arm. NAMS does not specify an ICER threshold but notes that generic hormone therapy is "among the most affordable prescription options for menopausal symptom management."

The Endocrine Society clinical practice guideline similarly supports estrogen therapy for hysterectomized women with menopausal symptoms, noting the favorable risk-benefit balance in the WHI E-alone subgroup of younger women.

Neither society has published a formal technology assessment with explicit cost-per-QALY thresholds, which represents a gap in the field.

Frequently asked questions

›

›

›

›

›

›

›

›

›

›

References

• Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004;291(14):1701-1712. PubMed
• Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med. 2003;349(6):523-534. PubMed
• LaCroix AZ, Chlebowski RT, Manson JE, et al. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy. JAMA. 2011;305(13):1305-1314. PubMed
• Manson JE, Allison MA, Rossouw JE, et al. Estrogen therapy and coronary-artery calcification. N Engl J Med. 2007;356(25):2591-2602. PubMed
• FDA. Premarin (conjugated estrogens) prescribing information. AccessData
• The NAMS 2022 Hormone Therapy Position Statement Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767-794. PubMed